InflaRx wins FDA emergency use authorization for Covid antibody
InflaRx’s monoclonal antibody vilobelimab has received emergency use authorization to treat critically ill Covid-19 patients on invasive mechanical ventilation.
Vilobelimab, which will be sold under the brand name Gohibic, was cleared for use in hospitalized adults within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, according to InflaRx. The German biotech said it’s ramping up production and will roll out the drug as soon as possible.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters